Despite that underperformance, I believe that the tide might be already turning in Cytek's favor: being a leading cellular analysis instrument maker with still a nicely expanding market TAM, CTKB's ...

$CTKB insiders have traded $CTKB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. We have seen 79 ...

Cytek Biosciences, Inc. (CTKB) shares ended the last trading session 5.1% higher at $5.73. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Insiders were net buyers of Cytek Biosciences, Inc.'s (NASDAQ:CTKB ) stock during the past year. That is, insiders bought ...

CTKB is the leader in full spectrum flow cytometry (FSFC). In its simplest form, flow cytometry analyzes samples for the kinds of cells or particles present and studies cells to determine their ...

RGAIA Investment Advisors, an independent, privately owned asset management firm recently published its second-quarter 2022 investor letter – a copy of which can be downloaded here. RGAIA Investment ...

We recently compiled a list of the 12 Cash-Rich Penny Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Cytek Biosciences, Inc. (NASDAQ:CTKB) stands against ...

Cytek Biosciences (NASDAQ:CTKB) just reported results for the first quarter of 2024. Cytek Biosciences reported earnings per share of -5 cents. This was below the analyst estimate for EPS of -4 cents.